文献速递膀胱癌与上尿路尿路上皮癌

卡介苗治疗前结核菌素皮肤试验可能影响非肌层浸润性膀胱癌疗效

Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer.
PubMed 文献 · J Urol · 2018-01-04

纳入498例接受辅助卡介苗治疗的非肌层浸润性膀胱癌患者,其中320例在治疗前1-2周接受纯化蛋白衍生物皮肤试验。结果显示,接受试验者的5年无复发生存率显著高于未接受者(66.6%±2.8% vs 59.1%±4.1%,p=0.048),但主要卡介苗相关副作用发生率也更高(24.1% vs 15.2%,p=0.02)。

要点

  • 卡介苗治疗前进行纯化蛋白衍生物皮肤试验与更高的5年无复发生存率相关。
  • 接受皮肤试验者主要卡介苗相关副作用发生率更高(24.1% vs 15.2%)。
  • 皮肤试验是肿瘤复发的独立保护因素(HR 0.72,p=0.04)。

核心结论

  • 卡介苗治疗前纯化蛋白衍生物皮肤试验可增强卡介苗疗效,但可能增加主要副作用发生率。

研究设计与样本

  • 研究纳入498例接受辅助卡介苗治疗的非肌层浸润性膀胱癌患者,其中320例在治疗前1-2周接受纯化蛋白衍生物皮肤试验,进行回顾性统计评估。

主要发现

  • 接受与未接受皮肤试验者的5年无复发生存率分别为66.6%±2.8%和59.1%±4.1%,差异显著(p=0.048)。
  • 两组无进展生存率无显著差异。
  • 多因素Cox回归显示,复发史(HR 1.59,p=0.02)、多发肿瘤(HR 1.95,p<0.01)、卡介苗Connaught菌株(HR 0.71,p=0.04)、7次及以上卡介苗灌注(HR 0.70,p=0.04)和接受皮肤试验(HR 0.72,p=0.04)与肿瘤复发独立相关。
  • 接受与未接受皮肤试验者的主要卡介苗相关副作用发生率分别为24.1%(77/320)和15.2%(27/178),差异显著(p=0.02)。

临床怎么用

  • 对于计划接受卡介苗治疗的非肌层浸润性膀胱癌患者,可考虑治疗前进行纯化蛋白衍生物皮肤试验以潜在改善肿瘤学结局,但需警惕主要副作用风险增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated the clinical impact of the purified protein derivative skin test prior to bacillus Calmette-Guérin therapy in patients with nonmuscle invasive bladder cancer treated with adjuvant bacillus Calmette-Guérin therapy. MATERIALS AND METHODS: A total of 498 patients with nonmuscle invasive bladder cancer treated with adjuvant bacillus Calmette-Guérin were included in study, of whom 320 underwent the purified protein derivative skin test 1 to 2 weeks prior to therapy. Oncologic outcomes and the rate of bacillus Calmette-Guérin related side effects were statistically evaluated. RESULTS: The mean ± SD 5-year recurrence-free survival rate in patients who did vs did not undergo the purified protein derivative skin test was 66.6% ± 2.8% and 59.1% ± 4.1%, respectively, which was significantly different (p = 0.048). No significant difference was observed in the progression-free survival rate between patients who did vs did not undergo the test. Multivariate Cox regression analysis revealed that a history of recurrence (HR 1.59, p = 0.02), multiple tumors (HR 1.95, p <0.01), the bacillus Calmette-Guérin Connaught strain (HR 0.71, p = 0.04), 7 or more bacillus Calmette-Guérin instillations (HR 0.70, p = 0.04) and undergoing the purified protein derivative skin test (HR 0.72, p = 0.04) were independently associated with tumor recurrence. Major bacillus Calmette-Guérin related side effects were noted in 77 of the 320 patients (24.1%) who did vs 27 of the 178 (15.2%) who did not undergo the test, which was significantly different (p = 0.02). CONCLUSIONS: The purified protein derivative skin test prior to bacillus Calmette-Guérin treatment enhances the therapeutic effects of this treatment and potentially results in a higher incidence of major bacillus Calmette-Guérin related side effects. Combination therapy with bacillus Calmette-Guérin using the purified protein derivative skin test may improve the oncologic outcomes of that therapy.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Niwa N, Kikuchi E, Matsumoto K, et al. Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer. J Urol. 2018. PMID: 29307686. doi:10.1016/j.juro.2017.12.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。